What this means
This study checked how a drug called ABBV-CLS-7262 may affect the heart's electrical reset in healthy adults. It is a registration, and no results have been posted yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Completed
- Who can join
- Ages 18–55
- Where
- 1 site, including Illinois
The science
- Registered title
- A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
- Trial ID
- NCT06310876 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Healthy
- What is tested
- ABBV-CLS-7262, ABBV-CLS-7262, Placebo, Moxifloxacin 400mg
- Sponsor
- Calico Life Sciences LLC
- Ages
- 18 Years to 55 Years
- Dates
- First posted Mar 15, 2024 · updated Jul 1, 2024
Registry summary
This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects.
Sites (1)
- AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States